Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer with N2 Disease

Shilpen Patel, Rachel E. Sanborn, Charles R. Thomas

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Non-small cell lung cancer remains the leading cause of cancer death in men and women, with a significant proportion of patients having locally advanced, unresectable disease at the time of diagnosis. Although significant advances in definitive therapy have been made with the concurrent administration of combination cytotoxic chemotherapy and thoracic irradiation, recurrence rates are still high, and long-term survival rates are suboptimal. The application of more modern radiation techniques and the addition of molecularly targeted systemic agents may add further benefit in survival.

Original languageEnglish (US)
Pages (from-to)393-401
Number of pages9
JournalThoracic Surgery Clinics
Issue number4
StatePublished - Nov 1 2008

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Definitive Chemoradiotherapy for Non-Small Cell Lung Cancer with N2 Disease'. Together they form a unique fingerprint.

Cite this